GERN - Geron Corporation

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Geron Corporation

149 Commonwealth Drive
Suite 2070
Menlo Park, CA 94025
United States

Full Time Employees15

Key Executives

Dr. John A. Scarlett M.D.Chief Exec. Officer, Pres and Director1.07MN/A66
Ms. Olivia Kyusuk BloomChief Financial Officer, Exec. VP of Fin. and Treasurer595.25kN/A48
Dr. Andrew J. Grethlein Ph.D.Exec. VP of Devel. and Technical Operations627.25kN/A53
Mr. Stephen N. Rosenfield J.D.Exec. VP, Gen. Counsel and Corp. Sec.498.3kN/A67
Mrs. Melissa A. Kelly BehrsExec. VP of Bus. Devel. and Portfolio & Alliance Management587.48kN/A53
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

Corporate Governance

Geron Corporation’s ISS Governance QualityScore as of February 1, 2018 is 4. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.